Genetic Technologies appoints Mike Tonroe as CFO
April 12 2021 - 8:15AM
Molecular diagnostics company Genetic Technologies Limited (ASX:
GTG; NASDAQ: GENE, “Company”), announces the appointment of Michael
Tonroe to the role of Chief Financial Officer, commencing on 28
June 2021.
Michael has over 25 years’ experience in overseeing the finance
function at both management and board-level positions for private
and listed companies in Australia, UK, US and Canada. He also has
extensive experience in the biotech space across both the financial
and company secretary roles having most recently managed both
functions for dual-listed Opthea Limited.
Commenting on the appointment, Chairman, Peter Rubinstein said,
“We are pleased to appoint Michael to the role of Chief Financial
Officer. Michael’s background and expertise in cross border
financial management will be a significant asset for GTG. In
conjunction with the recent appointment of Simon Morriss we are
well positioned with a strong senior leadership team across all
major functions with significant depth of experience and
expertise.”
In recognising the support of CFO Solutions Mr Rubinstein
stated: “We thank the team at CFO Solutions for their critical
outsourced financial support over the past few years as we
repositioned the business and established our longer-term strategy.
There professionalism and expertise have been highly appreciated
and we look forward to a smooth transition when Michael commences
with us at the end of June.”
Prior to his most recent role as Chief Financial Officer and
Company Secretary at dual-listed Opthea Michael was Chief Financial
Officer and Company Secretary at the Australian Synchrotron in
Melbourne. Michael also has extensive accounting expertise having
worked for both Deloitte and KPMG in the UK and Hong Kong.
On joining Genetic Technologies Michael stated, “I am excited to
be joining the team at Genetic Technologies. The depth of
experience sitting within this business already is impressive and I
am thrilled to once again utilise my skills and expertise in
working with companies as they transition from early-stage revenue
to full commercialisation. I look forward to working with the whole
team to establish the inhouse finance function to provide the
structure and support for Genetic Technologies long-term
strategy.”
Michael is a fellow of the Institute of Chartered Accountants in
England and Wales, a member of the Australian Institute of Company
Directors and holds a graduate degree in Business Studies from
Buckingham University, UK.
Approved by the Board of Directors Genetic Technologies
Limited.
Investor Relations (AUS) |
|
Investor Relations and Media (US) |
Stephanie Ottens |
|
Dave Gentry |
Market Eye |
|
1 800 RED CHIP (733 2447) |
M: +61 434 405 400 |
|
Cell: 407 491 4498 |
E: stephanie.ottens@marketeye.com.au |
|
E: dave@redchip.com |
About Genetic Technologies LimitedGenetic Technologies Limited
(ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics
company. GTG offers cancer predictive testing and assessment tools
to help physicians proactively manage patient health. The Company’s
lead products GeneType for Breast Cancer for non-hereditary breast
cancer and GeneType for Colorectal Cancer are clinically validated
risk assessment tests and are first in class. Genetic Technologies
is developing a pipeline of risk assessment products.
For more information, please visit www.gtglabs.com
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Apr 2023 to Apr 2024